Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

Rhea-AI Summary

Orexo AB extends patent protection for its nasal epinephrine powder product OX640 in the US, with a newly issued patent extending until November 2042. The company aims to strengthen its patent portfolio for OX640, enhancing long-term value and attracting potential partners for commercialization in the US market.

Positive

• Orexo AB receives extended patent protection for OX640 in the US until November 2042.
• The newly issued patent, US Patent No. 11,957,647, provides expanded scope of protection and longer patent term.
• The AmorphOX technology underlying OX640 has received eight patents, highlighting its uniqueness and value.
• Orexo plans to broaden the applications of AmorphOX with new substances, potentially leading to more patents.
• The extended exclusivity for OX640 enhances long-term value and increases attractiveness for potential commercialization partners in the US market.

Negative

• None.

UPPSALA, Sweden, April 17, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.

In August 2023, the USPTO granted the first patent for OX640 in the US, providing protection until May 2041. The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term, now extending until November 2042. Orexo has multiple patent applications filed on a global basis and expects to continuously strengthen the patent portfolio for OX640.

Nikolaj Sørensen, President and CEO, said: "Once again, I am pleased with the USPTO recognising the inventiveness of our OX640 product and the AmorphOX technology. This is the eighth patent based on the technology, underscoring its uniqueness and value. In parallel, we continue to broaden the applications of AmorphOX by testing the technology with new substances, which is expected to lead to more patents. The extended exclusivity for OX640 build additional long-term value and improves the attractiveness for potential partners for commercialization in the US market."

For further information, please contact:

Orexo AB (publ.)

Nikolaj Sørensen, President and CEO		Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00		Tel: +46 (0)18 780 88 00
Email: ir@orexo.com		Email: ir@orexo.com

 

About Orexo

Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube. 

About AmorphOX® 

Orexo's proprietary drug delivery platform, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure. 

About OX640

OX640 is based on AmorphOX and its powder-based technology provides excellent chemical and physical stability. In addition to providing allergic patients with a more convenient, needle-free alternative to auto-injectors currently on the market, an epinephrine product that

provides greater flexibility in relation to how it can be handled and stored should provide significant benefits to patients and healthcare systems worldwide.

The information was submitted for publication at 8 a.m. CET, on April 17, 2024.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-extends-patent-protection-for-its-nasal-epinephrine-powder-product-ox640-in-the-us,c3962545

The following files are available for download:

https://mb.cision.com/Main/694/3962545/2736584.pdf

Orexo_PR_Second Patent issued for OX640 in the US_April 17 2024

 

View original content:https://www.prnewswire.com/news-releases/orexo-extends-patent-protection-for-its-nasal-epinephrine-powder-product-ox640-in-the-us-302119094.html

SOURCE Orexo

FAQ

What is the newly issued US patent number for Orexo's nasal epinephrine powder product OX640?

The newly issued patent number is US Patent No. 11,957,647.

Until when has the patent protection for OX640 been extended in the US?

The patent protection for OX640 has been extended until November 2042.

How many patents are based on the AmorphOX technology underlying OX640?

There are eight patents based on the AmorphOX technology underlying OX640.

What is Orexo's plan regarding the applications of AmorphOX with new substances?

Orexo plans to test the AmorphOX technology with new substances, potentially leading to more patents.

How does the extended exclusivity for OX640 benefit Orexo?

The extended exclusivity for OX640 enhances long-term value and increases attractiveness for potential commercialization partners in the US market.